Financial Comparison: Opiant Pharmaceuticals (OPNT) versus Chiasma (CHMA)
Opiant Pharmaceuticals (NASDAQ: OPNT) and Chiasma (NASDAQ:CHMA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.
Volatility & Risk
Opiant Pharmaceuticals has a beta of -0.97, suggesting that its share price is 197% less volatile than the S&P 500. Comparatively, Chiasma has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.
Earnings & Valuation
This table compares Opiant Pharmaceuticals and Chiasma’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Opiant Pharmaceuticals||$14.97 million||5.14||$5.99 million||$2.89||13.14|
Opiant Pharmaceuticals has higher revenue and earnings than Chiasma. Chiasma is trading at a lower price-to-earnings ratio than Opiant Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
50.4% of Chiasma shares are held by institutional investors. 63.8% of Opiant Pharmaceuticals shares are held by insiders. Comparatively, 3.8% of Chiasma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares Opiant Pharmaceuticals and Chiasma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and recommmendations for Opiant Pharmaceuticals and Chiasma, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Opiant Pharmaceuticals beats Chiasma on 7 of the 9 factors compared between the two stocks.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.
Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company’s TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.
Receive News & Ratings for Opiant Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.